The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate

Simona Gatto, Barbara Scappini, Lan Pham, Francesco Onida, Michele Milella, Greg Ball, Clara Ricci, Vladimir Divoky, Srdan Verstovsek, Hagop M. Kantarjian, Michael J. Keating, Jorge E. Cortes, Miloslav Beran

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Background and Objectives. Imatinib mesylate (IM) is the choice treatment for Bcr/Abl-positive malignancies. Emergence of resistance to IM warrants the exploration of novel well-tolerated anticancer agents. We intended to evaluate the effect of PS-341 on proliferation, survival, and cellular events in Bcr/Abl-positive cells sensitive and resistant to IM, and to investigate the effect of PS-341 and IM in conjunction. Design and Methods. Bcr/Abl-positive cell lines sensitive (p210Bcr/Abl KBM5, p210Bcr/Abl KBM7, and p190Bcr/Abl Z-119) or resistant (KBM5-R) to IM were treated with PS-341 alone or in combination with IM. The effect on cell growth was determined using the MTT assay. Cell-cycle analysis was performed by propidium iodide staining. Apoptosis was evaluated by measurement of sub-G1 DNA content, annexin V binding, and caspase 3 activity assays. Levels of apoptotic proteins, P-IkBα, Bcr/Abl, and phosphorylated Bcr/Abl were determined by western blotting. NF-kB activity was evaluated by electromobility gel shift assays. Results. PS-341 exerted growth inhibition effects in IM-sensitive and -resistant cells. This phenomenon correlated with accumulation of cells in the G2/M phase of cell cycle; transient downregulation of NFκB DNA binding activity; downregulation of Bcl-xL; activation of caspase 3, induction of apoptosis; inhibition of expression and phosphorylation of Bcr/Abl. Sequential combination of PS-341 followed by IM demonstrated a synergistic pro-apoptotic effect in IM-sensitive cells; concomitant exposure was antagonistic. Interpretation and Conclusions. PS-341 suppresses growth and induces apoptosis in Bcr/Abl-positive cells sensitive and resistant to IM. The use of PS-341 should be explored in patients with chronic myelogenous leukemia resistant to IM. Trials of combinations of PS-341 and IM require cautious design.

Original languageEnglish
Pages (from-to)853-863
Number of pages11
JournalHaematologica
Volume88
Issue number8
Publication statusPublished - Aug 1 2003

Fingerprint

Proteasome Inhibitors
Apoptosis
Cell Line
Growth
Caspase 3
Bortezomib
Imatinib Mesylate
Cell Cycle
Down-Regulation
Propidium
NF-kappa B
G2 Phase
Annexin A5
DNA
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cell Division
Antineoplastic Agents
Western Blotting
Gels
Phosphorylation

Keywords

  • CML
  • PS-341
  • STI571-resistant cell lines

ASJC Scopus subject areas

  • Hematology

Cite this

The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. / Gatto, Simona; Scappini, Barbara; Pham, Lan; Onida, Francesco; Milella, Michele; Ball, Greg; Ricci, Clara; Divoky, Vladimir; Verstovsek, Srdan; Kantarjian, Hagop M.; Keating, Michael J.; Cortes, Jorge E.; Beran, Miloslav.

In: Haematologica, Vol. 88, No. 8, 01.08.2003, p. 853-863.

Research output: Contribution to journalArticle

Gatto, S, Scappini, B, Pham, L, Onida, F, Milella, M, Ball, G, Ricci, C, Divoky, V, Verstovsek, S, Kantarjian, HM, Keating, MJ, Cortes, JE & Beran, M 2003, 'The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate', Haematologica, vol. 88, no. 8, pp. 853-863.
Gatto, Simona ; Scappini, Barbara ; Pham, Lan ; Onida, Francesco ; Milella, Michele ; Ball, Greg ; Ricci, Clara ; Divoky, Vladimir ; Verstovsek, Srdan ; Kantarjian, Hagop M. ; Keating, Michael J. ; Cortes, Jorge E. ; Beran, Miloslav. / The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. In: Haematologica. 2003 ; Vol. 88, No. 8. pp. 853-863.
@article{88587b69ba8e457ea9d15edc9a358c93,
title = "The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate",
abstract = "Background and Objectives. Imatinib mesylate (IM) is the choice treatment for Bcr/Abl-positive malignancies. Emergence of resistance to IM warrants the exploration of novel well-tolerated anticancer agents. We intended to evaluate the effect of PS-341 on proliferation, survival, and cellular events in Bcr/Abl-positive cells sensitive and resistant to IM, and to investigate the effect of PS-341 and IM in conjunction. Design and Methods. Bcr/Abl-positive cell lines sensitive (p210Bcr/Abl KBM5, p210Bcr/Abl KBM7, and p190Bcr/Abl Z-119) or resistant (KBM5-R) to IM were treated with PS-341 alone or in combination with IM. The effect on cell growth was determined using the MTT assay. Cell-cycle analysis was performed by propidium iodide staining. Apoptosis was evaluated by measurement of sub-G1 DNA content, annexin V binding, and caspase 3 activity assays. Levels of apoptotic proteins, P-IkBα, Bcr/Abl, and phosphorylated Bcr/Abl were determined by western blotting. NF-kB activity was evaluated by electromobility gel shift assays. Results. PS-341 exerted growth inhibition effects in IM-sensitive and -resistant cells. This phenomenon correlated with accumulation of cells in the G2/M phase of cell cycle; transient downregulation of NFκB DNA binding activity; downregulation of Bcl-xL; activation of caspase 3, induction of apoptosis; inhibition of expression and phosphorylation of Bcr/Abl. Sequential combination of PS-341 followed by IM demonstrated a synergistic pro-apoptotic effect in IM-sensitive cells; concomitant exposure was antagonistic. Interpretation and Conclusions. PS-341 suppresses growth and induces apoptosis in Bcr/Abl-positive cells sensitive and resistant to IM. The use of PS-341 should be explored in patients with chronic myelogenous leukemia resistant to IM. Trials of combinations of PS-341 and IM require cautious design.",
keywords = "CML, PS-341, STI571-resistant cell lines",
author = "Simona Gatto and Barbara Scappini and Lan Pham and Francesco Onida and Michele Milella and Greg Ball and Clara Ricci and Vladimir Divoky and Srdan Verstovsek and Kantarjian, {Hagop M.} and Keating, {Michael J.} and Cortes, {Jorge E.} and Miloslav Beran",
year = "2003",
month = "8",
day = "1",
language = "English",
volume = "88",
pages = "853--863",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "8",

}

TY - JOUR

T1 - The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate

AU - Gatto, Simona

AU - Scappini, Barbara

AU - Pham, Lan

AU - Onida, Francesco

AU - Milella, Michele

AU - Ball, Greg

AU - Ricci, Clara

AU - Divoky, Vladimir

AU - Verstovsek, Srdan

AU - Kantarjian, Hagop M.

AU - Keating, Michael J.

AU - Cortes, Jorge E.

AU - Beran, Miloslav

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Background and Objectives. Imatinib mesylate (IM) is the choice treatment for Bcr/Abl-positive malignancies. Emergence of resistance to IM warrants the exploration of novel well-tolerated anticancer agents. We intended to evaluate the effect of PS-341 on proliferation, survival, and cellular events in Bcr/Abl-positive cells sensitive and resistant to IM, and to investigate the effect of PS-341 and IM in conjunction. Design and Methods. Bcr/Abl-positive cell lines sensitive (p210Bcr/Abl KBM5, p210Bcr/Abl KBM7, and p190Bcr/Abl Z-119) or resistant (KBM5-R) to IM were treated with PS-341 alone or in combination with IM. The effect on cell growth was determined using the MTT assay. Cell-cycle analysis was performed by propidium iodide staining. Apoptosis was evaluated by measurement of sub-G1 DNA content, annexin V binding, and caspase 3 activity assays. Levels of apoptotic proteins, P-IkBα, Bcr/Abl, and phosphorylated Bcr/Abl were determined by western blotting. NF-kB activity was evaluated by electromobility gel shift assays. Results. PS-341 exerted growth inhibition effects in IM-sensitive and -resistant cells. This phenomenon correlated with accumulation of cells in the G2/M phase of cell cycle; transient downregulation of NFκB DNA binding activity; downregulation of Bcl-xL; activation of caspase 3, induction of apoptosis; inhibition of expression and phosphorylation of Bcr/Abl. Sequential combination of PS-341 followed by IM demonstrated a synergistic pro-apoptotic effect in IM-sensitive cells; concomitant exposure was antagonistic. Interpretation and Conclusions. PS-341 suppresses growth and induces apoptosis in Bcr/Abl-positive cells sensitive and resistant to IM. The use of PS-341 should be explored in patients with chronic myelogenous leukemia resistant to IM. Trials of combinations of PS-341 and IM require cautious design.

AB - Background and Objectives. Imatinib mesylate (IM) is the choice treatment for Bcr/Abl-positive malignancies. Emergence of resistance to IM warrants the exploration of novel well-tolerated anticancer agents. We intended to evaluate the effect of PS-341 on proliferation, survival, and cellular events in Bcr/Abl-positive cells sensitive and resistant to IM, and to investigate the effect of PS-341 and IM in conjunction. Design and Methods. Bcr/Abl-positive cell lines sensitive (p210Bcr/Abl KBM5, p210Bcr/Abl KBM7, and p190Bcr/Abl Z-119) or resistant (KBM5-R) to IM were treated with PS-341 alone or in combination with IM. The effect on cell growth was determined using the MTT assay. Cell-cycle analysis was performed by propidium iodide staining. Apoptosis was evaluated by measurement of sub-G1 DNA content, annexin V binding, and caspase 3 activity assays. Levels of apoptotic proteins, P-IkBα, Bcr/Abl, and phosphorylated Bcr/Abl were determined by western blotting. NF-kB activity was evaluated by electromobility gel shift assays. Results. PS-341 exerted growth inhibition effects in IM-sensitive and -resistant cells. This phenomenon correlated with accumulation of cells in the G2/M phase of cell cycle; transient downregulation of NFκB DNA binding activity; downregulation of Bcl-xL; activation of caspase 3, induction of apoptosis; inhibition of expression and phosphorylation of Bcr/Abl. Sequential combination of PS-341 followed by IM demonstrated a synergistic pro-apoptotic effect in IM-sensitive cells; concomitant exposure was antagonistic. Interpretation and Conclusions. PS-341 suppresses growth and induces apoptosis in Bcr/Abl-positive cells sensitive and resistant to IM. The use of PS-341 should be explored in patients with chronic myelogenous leukemia resistant to IM. Trials of combinations of PS-341 and IM require cautious design.

KW - CML

KW - PS-341

KW - STI571-resistant cell lines

UR - http://www.scopus.com/inward/record.url?scp=0141761420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141761420&partnerID=8YFLogxK

M3 - Article

VL - 88

SP - 853

EP - 863

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 8

ER -